Introduction
============

Tubulin tyrosine ligase-like 5 (*TTLL5*; Gene ID: 19963; OMIM: [612268](https://www.ncbi.nlm.nih.gov/omim/?term=612268)) is a 32-exon gene that encodes the largest protein of 13 members of the tubulin tyrosine ligase-like (TTLL) super-family ([Figure 1](#f1){ref-type="fig"}) \[[@r1]-[@r4]\]. TTLL5 was found to be expressed in the heart and skeletal muscle \[[@r5]\] but shows expression in other tissues, such as the brain \[[@r6]\] and the eye ([Hs.709609](file:///C:\\\\Users\\\\Cynthia\\\\Documents\\\\WORK\\\\01January2017\\\\434358-MolVis\\\\(http:\\\\www.ncbi.nlm.nih.gov\\\\UniGene\\\\ESTProfileViewer.cgi%3fuglist=Hs.709609)). The TTLL5 protein includes a core tubulin tyrosine ligase (TTL) domain in its N-terminus and a coactivator interaction domain (CID) followed by three receptor interaction domains (RID) at its C-terminus \[[@r2],[@r4]\]. Defects in the *TTLL5* gene have been reported to affect the correct function of sperm flagella \[[@r4]\], as well as trigger cone-dominated retinopathy, as cone-rod or cone dystrophy (CRD or CD) \[[@r7],[@r8]\]. The latter represents a heterogeneous group of inherited retinal diseases characterized by primary cone and secondary rod photoreceptor degeneration or no rod photoreceptor degeneration involvement leading to progressive loss of central vision associated with photophobia and color vision abnormalities in childhood or early adult life, due to cone degeneration. Subsequently, patients experience dim light vision disturbances and constriction of the peripheral visual field, due to rod degeneration leading to a severe loss of vision and complete blindness in some cases \[[@r9]\]. In contrast, incomplete congenital stationary night blindness (icCSNB) is represented largely by nonprogressive functional defect, in which the signal transmission from rod and cone photoreceptors to the adjacent ON and OFF bipolar cells is affected, while the structure of the photoreceptors is globally maintained \[[@r10]\]. However, due to several overlapping clinical features of CRD and icCSNB, these disorders can be confounded.

![*TTLL5* gene and reported mutations. **A**: Schematic drawing of exon organization and the corresponding location of mutations in the *TTLL5* gene. **B**: The TTLL5 protein structure shows the predicted consequence of the reported mutations in relation to the domain organization, composed of a core tubulin tyrosine ligase-like (TTLL) domain, a multivalent microtubule recognition region (c-MTBD), a cofactor interaction domain (CID), and a receptor interaction domain (RID). Black arrows point out the mutations reported in this paper, white dots represent missense mutations, and black dots represent nonsense mutations. Amino acids (aa).](mv-v23-131-f1){#f1}

Initially, mainly based on in vitro studies, it was hypothesized that TTLL5 plays an important role in the polyglutamylation of primary cilia \[[@r11]-[@r14]\]. Immunolocalization studies performed by Sergouniotis et al. in human and murine retinas placed TTLL5 in rods and cones, at the base of the connecting cilium, between the basal body and the ciliary axoneme (or outer segment). This staining was more noteworthy in the cones than in the rods \[[@r7]\]. Furthermore, in contrast to rods, cones are characterized by open membrane disks that lack the complete sheath of the plasma membrane, and in the deficiency of TTLL5, one could foresee more severe damage to cones than to rods \[[@r7]\]. However, mice that lacked functional TTLL5 showed changes in tubulin glutamylation levels only in sperm and no phenotype related to retinal function \[[@r4]\]. Therefore, disruption of tubulin glutamylation does not explain the retinal phenotype. Interestingly, recently, a probable connection between TTLL5 and the functional variant of the retinitis pigmentosa GTPase regulator (RPGR), RPGR^ORF15^, in the photoreceptor cilia was reported \[[@r15],[@r16]\]. It was suggested that TTLL5 binds the basic domain (BD) of RPGR^ORF15^ with its CID, exclusive to TTLL5 among other members of the TTLL super-family. Therefore, TTLL5 is most likely responsible for the glutamylation of RPGR^ORF15^ in its glutamic acid-glycine-rich repetitive region. These findings render *TTLL5* a noteworthy disease-causing candidate gene of cone-dominated retinal dystrophies. The most recent reports associate nine presumed loss-of-function mutations in *TTLL5* (c.349C\>T, p.Gln117\*; c.401del, p.Leu134Argfs\*45; c.1586_1589del, p.Glu529Valfs\*2; c.1627G\>T, p.Glu543\*; c.1627G\>A, p.Glu543Lys; c.1782del, p.Asp594Glufs\*29; c.2132_2135dup, p.Met712Ilefs\*15; c.2266A\>T, p.Ile756Phe; c.3354G\>A, Trp1118\*) with retinal dystrophies ([Figure 1](#f1){ref-type="fig"}) \[[@r7],[@r8]\]. Although missense and truncating mutations were linked to an isolated retinal phenotype \[[@r7]\], only truncating mutations appear to disrupt the functions of photoreceptors and spermatozoa \[[@r8]\], thus rendering no apparent genotype or phenotype correlation. Moreover, it was found that *Rpgr* null mice exhibit a similar phenotype compared to *Ttll5* mutant mice and are characterized by photoreceptor degeneration and opsin mislocalization \[[@r15],[@r17]-[@r20]\]. Bearing in mind the involvement of *TTLL5* in CRD and CD and that the respective protein interacts with RPGR^ORF15^, it is important to include this gene in the molecular study of patients affected with retinal dystrophy in general. Here, we identified in a previously misdiagnosed icCSNB case a splice-site mutation in intron 3 of *TTLL5* (c.182--3_182--1delinsAA). Reinvestigation of the clinical data corrected the diagnosis to CD.

Methods
=======

Clinical diagnosis and sample collection
----------------------------------------

Research procedures were conducted in accordance with institutional guidelines and the Declaration of Helsinki; institutional review board approvals were obtained from the participating universities and the national ministry of health of the participating center. Before genetic testing, informed consent was obtained from all family members. Ophthalmic examinations were performed on all subjects. This examination included best-corrected Snellen visual acuity measurement, fundoscopy, the Farnsworth D-15 color vision test, a full-field electroretinogram (ERG) that incorporated the International Society for Clinical Electrophysiology of Vision standards and methodology previously described \[[@r21]-[@r23]\], fundus autofluorescence (FAF) and infrared (IR), and spectral-domain optical coherence tomography (SD-OCT).

Sanger sequencing of icCSNB known and candidate genes
-----------------------------------------------------

The coding exonic and flanking intronic regions of the known genes underlying icCSNB (*CACNA1F* [NM_005183.3](https://www.ncbi.nlm.nih.gov/nuccore/NM_005183.3), OMIM [300110](https://www.ncbi.nlm.nih.gov/omim/?term=300110); *CABP4* [NM_145200.3](https://www.ncbi.nlm.nih.gov/nuccore/NM_145200.3), OMIM [608965](https://www.ncbi.nlm.nih.gov/omim/?term=608965); *CACNA2D4* [NM_172364.4](https://www.ncbi.nlm.nih.gov/nuccore/NM_172364.4), OMIM [608171](https://www.ncbi.nlm.nih.gov/omim/?term=608171)) \[[@r10],[@r24]-[@r27]\] and the candidate genes (*ELFN1* [NM_001128636.2](https://www.ncbi.nlm.nih.gov/nuccore/NM_001128636.2), OMIM [614964](https://www.ncbi.nlm.nih.gov/omim/?term=614964) \[[@r28]\]; *GNB3* [NM_001297571.1](https://www.ncbi.nlm.nih.gov/nuccore/NM_001297571.1), OMIM [139130](https://www.ncbi.nlm.nih.gov/omim/?term=139130) \[[@r29],[@r30]\]) were directly Sanger sequenced on the index patient. PCR conditions are available upon request.

Whole exome sequencing
----------------------

Exons of genomic DNA samples were captured using Agilent in-solution enrichment methodology (SureSelect SureSelect XT Clinical Research Exome, Agilent, Massy, France) with their biotinylated oligonucleotides probes library (SureSelect XT Clinical Research Exome - 54 Mb, Agilent), followed by paired-end 75 bases massively parallel sequencing on the Illumina HiSeq 4000 system (Illumina, San Diego, CA) \[[@r31]\]. Base calling was achieved using the Illumina Real-Time Analysis software sequence pipeline (2.7.3) with default parameters. Bioinformatics analysis of the resultant sequencing data was done using the IntegraGen constitutional DNA pipeline V2 (IntegraGen, Evry, France).

To rapidly identify the pathogenic variant, WES was applied to all three members of this consanguineous family ([Figure 2](#f2){ref-type="fig"}). Filtering approaches were subsequently applied to identify candidate mutation(s). Referenced variants that occurred homozygously or heterozygously with a minor allele frequency (MAF) \>0.005 in [dbSNP137](https://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi?view+summary=view+summary&build_id=137), HapMap \[[@r32]\], [1000 Genomes](http://browser.1000genomes.org/index.html) \[[@r33]\], and the NHLBI Exome Sequencing Project Exome Variant Server ([EVS](http://evs.gs.washington.edu/EVS/)) \[[@r34]\] were removed \[[@r35]-[@r37]\].

![Novel disease-causing variants in *TTLL5* in cone dystrophy: Pedigree of the index patient with disease-causing variants in *TTLL5* and cosegregation analysis. The index patient, the proband, is the individual II-3, marked with an arrow. Square symbol=male, round symbol=female, filled symbol=affected, unfilled symbol=unaffected, double line=consanguinity. Underneath the symbols, the sequence electropherograms of the disease-causing variant in *TTLL5* is found homozygously in the proband and heterozygously in the parents. The underlined letters correspond to the modifications of the sequence induced by this disease-causing variant.](mv-v23-131-f2){#f2}

Molecular validation of the candidate variants
----------------------------------------------

The novel mutation in the *TTLL5* gene (c.182--3_182--1delinsAA) was validated using conventional Sanger sequencing according to the manufacturer's protocols (3730 DNA Analyzer, Applied Biosystems, Weiterstadt, Germany) and tested for cosegregation of the phenotype within the family. However, given that consanguinity among parents was reported for this family, homozygous variants represent the most likely candidate, although this does not completely exclude underlying causative compound-heterozygous mutations \[[@r38]\].

Results
=======

Phenotype and clinical investigations of the affected patient
-------------------------------------------------------------

The index patient was a 9-year-old boy ([Figure 2](#f2){ref-type="fig"}, II-3), corrected for myopia since 3 years of age, who always had difficulty watching television and reading. He never complained of night blindness, peripheral vision loss, and dyschromatopsia, but he had moderate photophobia and wore photochromic glasses. The disease course seemed not progressive. Visual acuity was 20/30 in both eyes with −1.75(−2.25)40° oculus dexter (OD) and −6.25(−1.50)5° oculus sinister (OS). The anterior segments were normal, and the lenses were transparent. The fundus showed a moderate overall depigmentation, absence of the foveal reflex with a slight narrowing of the retinal vessels, and moderate pallor of the optic disc but no atrophy or pigment deposits, which was also confirmed with infrared reflectance images ([Figure 3A,B](#f3){ref-type="fig"}). The retinal autofluorescence images were almost normal except a moderate perifoveal hyperautofluorescence ([Figure 3C](#f3){ref-type="fig"}). Optical coherence tomography (OCT) showed a normal peripheral retina, but we noted bilaterally moderate macular thinning with the ellipsoid zone moderately decreased in the thickness in the temporal part of the fovea ([Figure 3D](#f3){ref-type="fig"}). Color vision testing with Lanthony D-15 HUE color tests showed a bilateral moderate blue-yellow axis of color confusion (not shown). In mixed kinetic and static perimetry, the peripheral isopter IIIc was normal on each side, 90° in temporal and 45° in nasal, but there was a medium decrease in the retinal sensitivity of the central 30°, including in the macular area ([Figure 3E](#f3){ref-type="fig"}). On the ISCEV ERG, the amplitude of the scotopic responses was normal ([Figure 3F](#f3){ref-type="fig"}). However, the photopic responses to a single flash were reduced and showed a moderate electronegative aspect. The 30 Hz flicker responses were reduced to about 30% of the normal value. In the oscillatory potentials (OP), OP1 was absent; in the others, OPs were present but diminished in amplitude (not shown). Due to the reduced photopic responses, the decreased visual acuity, presence of myopia, no obvious disease progression, and absence of night blindness, it was concluded that the patient had an atypical type of icCSNB. Although the name incomplete CSNB is misleading, patients with this disease often reveal the absence of night blindness \[[@r10]\]. Two older sisters had no particular visual difficulties. His parents, both unaffected, were second cousins of Swiss origin. There was no history of this disease in the family. Therefore, the patient was an isolated case, which, given the parental consanguinity, suggested an autosomal recessive mode of inheritance. X-linked heredity could not be excluded, but as the mother had five unaffected brothers, this mode of inheritance was not supported.

![Clinical investigations of the patient with a homozygous mutation in *TTLL5*. A: Fundus photographs of the right (left side) and left (right side). There is no macular atrophy or pigment deposits. **B**, **C**: The infrared reflectance images (**B**) and fundus autofluorescence (**C**) show a moderate increase in perifoveal autofluorescence. **D**: Optical coherence tomography of the right (up) and left (down) eyes with a selection of peripheral (left) and macular (right) slices for each side show that the periphery is normal while there are subtle changes in the perifoveal area with attenuation of the ellipsoid zone. **E**: The kinetic (peripheral isopter) and static visual field shows a normal peripheral visual field with a general decrease in retinal sensitivity in the central 30° in accordance with cone dysfunction. **F**: The International Society for Clinical Electrophysiology of Vision (ISCEV) electroretinogram (ERG) indicates a normal rod function (dark-adapted ERG) while the amplitude values of the cone function (light-adapted ERG) corresponded to 30% of the normal values.](mv-v23-131-f3){#f3}

Genotype assessment and mutation cosegregation in the family
------------------------------------------------------------

Mutation screening showed that none of the known genes underlying icCSNB and the other CSNB candidate genes presented any disease-causing variant. Therefore, WES was performed for the trio, and sequence filtration isolated 15 putative variants (Appendix 1) from 194 insertions/deletions (InDels) and 1,597 single nucleotide variants (SNVs), as the splice-site mutation in intron 3 of the *TTLL5* gene, c.182--3_182--1delinsAA (Appendix 2) selected for further cosegregation studies. For all subjects, the overall sequencing coverage of the captured regions was 92% and 88% for 10X and 25X depth of coverage, respectively, resulting in a mean sequencing depth of 109X per base (Appendix 3). Both unaffected parents were found to be heterozygous for this variant, at 40% and 48% in the mother and father, respectively, and the proband was homozygous for this variant, at 99%. The sequencing depth at this position was 132X and 124X in the mother and father, respectively, and 141X for the proband (Appendix 2). This c.182--3_182--1delinsAA mutation in *TTLL5* was validated in the index patient and the unaffected parents with direct Sanger sequencing ([Figure 2](#f2){ref-type="fig"}).

Discussion
==========

The patient studied, a 9-year-old boy, presented with a condition that appeared to be congenital and stationary. The clinical presentation initially reflected icCSNB because of myopia, a decrease in visual acuity, abnormal oscillatory potentials, and reduced amplitudes on the 30 Hz flicker ERG but was atypical because there were no clear electronegative responses. However, the subsequent genetic analysis excluded any disease-causing mutations in known genes underlying icCSNB (*CACNA1F*, *CABP4*, and *CACNA2D4*), as well in other candidate CSNB genes (*ELFN1* and *GNB3*). Following WES analysis of the family, a homozygous splice-site mutation in intron 3 of *TTLL5* (c.182--3_182--1delinsAA) was found cosegregating within the phenotype in the family. Splice-site prediction software (BDGP: [Splice Site](http://www.fruitfly.org/seq_tools/splice.html) Prediction by Neural Network) forecasts the loss of the constitutive acceptor site (c.182--2_182--1) and predicts an alternative constituent acceptor site (nucleotides AG at position c.203_204), with a score of 0.9 by BDGP), which would lead to a truncating mutation p.(Glu61Aspfs\*19) or alternatively nonsense mediated mRNA decay (Appendix 4, [Figure 1](#f1){ref-type="fig"}). This will most likely lead to the absence of RPGR^ORF15^ glutamylation and thus lead to the retinal phenotype \[[@r15]\]. Moreover, although in relation to retinal degeneration and pathogenic variants in *TTLL5* no strong genotype or phenotype correlation exists (CRD versus CD), patients who present truncating mutations seemed to have a higher probability of reduced fertility \[[@r8]\]. Thus, as the index patient is a boy who possesses a truncating mutation, which is predicted to abolish all functional domains when the mutant protein is formed, it is likely that he will have reduced fertility. This finding may lead to appropriate information provided to the patient at adult age that can eventually be addressed at a fertility clinic.

Recently, defects in the *TTLL5* gene were associated with retinal dystrophies that affect primarily cones, leading to either moderate cone dystrophies with onset at adult stages or cone rod dystrophies that start earlier. In total, 14 patients from 11 families have been reported with *TTLL5* mutations \[[@r7],[@r8]\]. The following clinical signs were described for some or all of the patients: a variable degree of myopia, dyschromatopsia, reduced visual acuity, high-density concentric perifoveal rings surrounding irregular foveal autofluorescence or hypoautofluorescent patches in the fovea and parafovea combined with irregular autofluorescence outside the foveal region upon fundus autofluorescence imaging, optical coherence tomography abnormalities consistent with photoreceptor loss confined to the foveal region or observed throughout the scan, and mainly altered severely reduced photopic responses due to the cone defect with some patients showing altered scotopic responses due to rod involvement. In contrast, icCSNB is a nonprogressive retinal disorder mainly characterized by the presence or absence of night blindness, decreased visual acuity, photophobia with reduced scotopic b-wave responses and reduced photopic responses, and often high myopia. Due to the reduced photopic responses, the decreased visual acuity, the presence of myopia, no obvious disease progression, and the absence of night blindness, it was concluded that the patient in the study had an atypical type of icCSNB. However, detailed clinical investigation of this patient showed moderate overall depigmentation, a slight narrowing of the retinal vessels, moderate pallor of the optic disc, moderate perifoveal hyperautofluorescence, and bilateral macular thinning with the ellipsoid zone moderately decreased in thickness in the temporal area of the fovea.

Most of the clinical documentation of the previously described patients with *TTLL5* mutations was presented for patients older than 30 years old with a progressive disease. In this study, the observation of a young patient (9 years) led to the misdiagnosis of a stationary disease, pointing out the difficulty of making the correct clinical diagnosis of a *TTLL5* dystrophy at an early stage without the help of molecular testing. In the present study, WES analysis provided prompt diagnosis for this family; thus, the use of this technique to refine the diagnosis is highlighted. In addition, sequencing of exomes of trios should become an early part of the diagnostic workup of retinal dystrophy. An alternative, rapid, and less bioinformatically demanding method would have been to investigate the patient before WES was performed with targeted next-generation sequencing covering all genes underlying inherited retinal disorders \[[@r9]\].
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